News headlines about XBiotech (NASDAQ:XBIT) have been trending positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. XBiotech earned a news impact score of 0.26 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near term.
XBiotech (NASDAQ:XBIT) traded up 2.16% during mid-day trading on Friday, reaching $4.73. The company’s stock had a trading volume of 128,116 shares. XBiotech has a 12-month low of $2.77 and a 12-month high of $20.18. The company has a 50-day moving average price of $4.78 and a 200-day moving average price of $10.49. The firm’s market cap is $166.92 million.
Several equities research analysts have recently weighed in on XBIT shares. Stifel Nicolaus upgraded XBiotech from a “hold” rating to a “buy” rating in a report on Saturday, June 3rd. ValuEngine lowered XBiotech from a “sell” rating to a “strong sell” rating in a report on Saturday, June 10th. Noble Financial reaffirmed a “hold” rating and set a $13.00 price target on shares of XBiotech in a research report on Friday, April 21st. Finally, Zacks Investment Research raised XBiotech from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Saturday, May 20th.
ILLEGAL ACTIVITY WARNING: “XBiotech (XBIT) Getting Positive Media Coverage, Study Shows” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/07/29/xbiotech-xbit-given-news-impact-score-of-0-26-updated-updated-updated.html.
XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.
Receive News & Ratings for XBiotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.